Treatment of juvenile idiopathic arthritis-associated uveitis: Challenges and update

Current Opinion in Rheumatology

Volumn 23, Issue 5, 2011, Pages 432-436

  Rabinovich, C Egla ^a  

^a DUKE CHILDREN S HOSPITAL   (United States)

Author keywords

juvenile idiopathic arthritis; risk factors; treatment; uveitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYDRIATIC AGENT; PLACEBO; PREDNISONE; RITUXIMAB;

ARTHRITIS; BAND KERATOPATHY; BIOLOGICAL THERAPY; CATARACT; CELL ACTIVITY; CLINICAL TRIAL; COMORBIDITY; DATA BASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; EYE DISEASE; HIGH RISK POPULATION; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; JUVENILE RHEUMATOID ARTHRITIS; KERATOPATHY; PAPILLITIS; POSTERIOR SYNECHIAE; PRIORITY JOURNAL; RELAPSE FREE SURVIVAL; REMISSION; RETINA MACULA CYSTOID EDEMA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCLERITIS; SEX ROLE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VISUAL IMPAIRMENT;

ADMINISTRATION, OPHTHALMIC; ADRENAL CORTEX HORMONES; ANTIMETABOLITES; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL AGENTS; CHILD; FEMALE; HUMANS; MALE; METHOTREXATE; RISK FACTORS; UVEITIS;

EID: 80052035973     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328349c324     Document Type: Review

References (35)

1. Rabinovich CE. Use of antitumor necrosis factor inhibitors in pediatric uveitis. Curr Opin Rheumatol 2007; 19:482-486. (Pubitemid 47344242)
2. Holland GN. A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2007; 105:344-364.
3. Heinz C, Mingels A, Goebel C, et al. Chronic uveitis in children with and without juvenile idiopathic arthritis: differences in patient characteristics and clinical course. J Rheumatol 2008; 35:1403-1407. (Pubitemid 352000792)
4. Marvillet I, Terrada C, Quatier P, et al. Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine 2009; 76:383-388.
5. Keenan JD, Tessler HH, Goldstein DA. Granulomatous inflammation in juvenile idiopathic arthritis-related uveitis. J AAPOS 2008; 12:546-550.
6. Bolt I, Cannizzaro E, Seger R, Saurenmann R. Risk factors and long-term outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland. J Rheumatol 2008; 35:703-706. (Pubitemid 351500070)
7. Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis. Arthritis Rheum 2007; 56:647-657.
8. Kump LI, Cervantes-Castaneda RA, Androudi SN, Foster CS. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology 2005; 112:1287-1292. (Pubitemid 40916939)
9. Thorne JE, Woreta F, Kedhar SR, et al. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 2007; 143:840-846.
10. Standardization of Nomenclature (SUN) Working Group. Standardization of Uveitis Nomenclature for Reporting Clinical Data. Results of the First International Workshop. Am J Ophthalmol 2005; 140:509-516.
11. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25:1991-1994. (Pubitemid 28459316)
12. Heiligenhaus A, Niewerth M,Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology 2007; 46:1015-1019. (Pubitemid 47062514)
13. Cassidy J, Kivlin J, Lindsley C, et al. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006; 117:1843-1845. (Pubitemid 46071421)
14. Edelsten C, Lee V, Bentley CR, et al. An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol 2002; 86:51-56. (Pubitemid 34074885)
15. Holland GN, Denove CS, Yu F. Chronic anterior uveitis in children: clinical characteristic and complications. Am J Ophthalmol 2009; 147:667-678.
16. Saurenmann RK, Levin AV, Feldman BM, et al. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62:1824-1828.
17. Ayuso VK, ten Cate HAT, van der Does P, et al. Male gender as a risk factor for complications in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2010; 149:994-999.
18. Ayuso VK, ten Cate HAT, van der Does P, et al. Male gender and poor visual outcome in uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol 2010; 149:987-993.
19. Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010; 117:1436-1441.
20. Ayuso VK, van de Winkel EL, Rothova A, de Boer JK. Relapse rate of uveitis postmethotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 2011; 151:217-222.
21. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115:1826-1832.
22. Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol 2011; 95:209-213.
23. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-a treatment: a possible promotor in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010; 35:751-756.
24. Pato E, Munoz-Fernandez S, Francisco F, et al. Systemic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum 2011; 40:314-323.
25. Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res 2011; 63:612-618.
26. Kahn P, Weiss M, Imundo L, Levy DM. Favorable response to high dose infliximab for refractory childhood uveitis. Ophthalmology 2006; 133:860-864.
27. Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term followup. Am J Ophthalmol 2007; 144:844-849.
28. Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: a case report. J Rheumatol 2008; 35:1897-1898.
29. Zulian F, Balzartin M, Falcini F, et al. Abatacept for severe antitumor necrosis factor a refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010; 62:821-825.
30. Kenawy N, Clearly G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2011; 249:297-300.
31. Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on article by Zulian et al. Arthritis Care Res 2011; 63:307-308.
32. Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005; 112:764-770. (Pubitemid 40631493)
33. Sen HN, Levy-Clarke G, Faia LJ, et al. High dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009; 148:696-703.
34. Miserocchi E, Pontikaki I, Modorati G, et al. Rituximab for uveitis. Ophthalmology 2011; 118:223-224.
35. Heilignenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011 March 4. [Epub ahead of print]